Van Rengen - Versele SRL
Van Rengen - Versele reported total assets of €1.92m at the end of the 2026 financial year (annual accounts filed with the NBB on 28 Sep 2026).
The score of Van Rengen - Versele shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Equity +31 % Total assets +15 %
Accounts of the company itself (not consolidated).
The full file covers 11 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Van Rengen - Versele's annual accounts
Filed annual accounts
- Year ended 31 Mar 2026filed on 28 Sep 2026
- Year ended 31 Mar 2025filed on 29 Sep 2025
- Year ended 31 Mar 2024filed on 30 Sep 2024
- Year ended 31 Mar 2023filed on 25 Sep 2023
- Year ended 31 Mar 2022filed on 28 Oct 2022
Van Rengen - Versele's financial analysis
- Solvency81.6%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Van Rengen - Versele
Van Rengen - Versele's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0884.115.408
- VAT number
- BE0884115408
- Peppol
- Registered · 0208:0884115408 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 10 Oct 2006
- Registered office
- 9667 Horebeke
- Latest accounts
- 2026 · filed on 28 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Van Rengen - Versele (SRL) has been based in Horebeke since 2006, active in: retail sale of pharmaceutical products. For 2026, it reports a net profit of 130,770 € and equity of €1.56m; its revenue is not published. Its solvency stands at 81.6%, above the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Van Rengen - Versele
Companies in the same business, of comparable size and area, outside its group.
- Crobephar Business and other management consultancy activities Quévy · balance sheet €1.56m
- TM Pharma Business and other management consultancy activities Edegem · balance sheet €1.68m
- Van Haren Management Business and other management consultancy activities Sprimont · balance sheet €2.60m
- KYKS Business and other management consultancy activities Forest · balance sheet €2.70m
- Farma Danaux Retail sale of pharmaceutical products Wetteren · balance sheet €2.07m
- Antares Invest Retail sale of pharmaceutical products Celles (lez-Tournai) · balance sheet €1.80m
- K & K Management Retail sale of pharmaceutical products Mol · balance sheet €2.36m
- La Roche Pharma Retail sale of pharmaceutical products La Roche-en-Ardenne · balance sheet €1.97m
Frequently asked questions about Van Rengen - Versele
What is the revenue of Van Rengen - Versele?
Van Rengen - Versele files its accounts in a format where revenue is optional: it is not published for 2026.
What is the VAT number of Van Rengen - Versele?
In Belgium, the VAT number is the company number prefixed with BE: BE0884115408 for Van Rengen - Versele, if the company is VAT-registered. Its company number (CBE) is 0884.115.408.
Where is the registered office of Van Rengen - Versele?
According to the CBE register, the registered office of Van Rengen - Versele is in 9667 Horebeke.
What is the equity of Van Rengen - Versele?
At the close of the 2026 financial year, the equity of Van Rengen - Versele amounts to 1,564,185 €, a solvency of 81.6% of total assets.
Who manages Van Rengen - Versele?
The register lists 2 active mandates at Van Rengen - Versele. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Van Rengen - Versele
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →